nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetylsalicylic acid—TP53—colon cancer	0.401	0.734	CbGaD
Acetylsalicylic acid—PTGS2—colon cancer	0.0784	0.144	CbGaD
Acetylsalicylic acid—ABCB1—colon cancer	0.0666	0.122	CbGaD
Acetylsalicylic acid—SLC22A7—Fluorouracil—colon cancer	0.0596	0.25	CbGbCtD
Acetylsalicylic acid—SLC22A7—Methotrexate—colon cancer	0.0329	0.138	CbGbCtD
Acetylsalicylic acid—ALB—Irinotecan—colon cancer	0.0225	0.0943	CbGbCtD
Acetylsalicylic acid—ALB—Fluorouracil—colon cancer	0.0216	0.0905	CbGbCtD
Acetylsalicylic acid—CYP2C9—Capecitabine—colon cancer	0.0196	0.0822	CbGbCtD
Acetylsalicylic acid—CYP2C8—Fluorouracil—colon cancer	0.0167	0.0699	CbGbCtD
Acetylsalicylic acid—SLC22A6—Methotrexate—colon cancer	0.014	0.0586	CbGbCtD
Acetylsalicylic acid—ALB—Methotrexate—colon cancer	0.0119	0.0499	CbGbCtD
Acetylsalicylic acid—ABCB1—Irinotecan—colon cancer	0.0118	0.0493	CbGbCtD
Acetylsalicylic acid—CYP2C9—Fluorouracil—colon cancer	0.0116	0.0488	CbGbCtD
Acetylsalicylic acid—ABCB1—Vincristine—colon cancer	0.0103	0.0431	CbGbCtD
Acetylsalicylic acid—ABCB1—Methotrexate—colon cancer	0.00623	0.0261	CbGbCtD
Acetylsalicylic acid—TP53—endothelium—colon cancer	0.00301	0.0415	CbGeAlD
Acetylsalicylic acid—NFKBIA—endothelium—colon cancer	0.00296	0.0408	CbGeAlD
Acetylsalicylic acid—TP53—blood vessel—colon cancer	0.00278	0.0382	CbGeAlD
Acetylsalicylic acid—NFKBIA—blood vessel—colon cancer	0.00273	0.0376	CbGeAlD
Acetylsalicylic acid—TP53—gall bladder—colon cancer	0.00261	0.036	CbGeAlD
Acetylsalicylic acid—NFKBIA—gall bladder—colon cancer	0.00257	0.0354	CbGeAlD
Acetylsalicylic acid—TP53—embryo—colon cancer	0.00166	0.0228	CbGeAlD
Acetylsalicylic acid—NFKBIA—embryo—colon cancer	0.00163	0.0224	CbGeAlD
Acetylsalicylic acid—HSPA5—embryo—colon cancer	0.0016	0.022	CbGeAlD
Acetylsalicylic acid—RPS6KA3—embryo—colon cancer	0.00136	0.0187	CbGeAlD
Acetylsalicylic acid—TP53—epithelium—colon cancer	0.00135	0.0186	CbGeAlD
Acetylsalicylic acid—NFKBIA—epithelium—colon cancer	0.00133	0.0183	CbGeAlD
Acetylsalicylic acid—HSPA5—epithelium—colon cancer	0.0013	0.0179	CbGeAlD
Acetylsalicylic acid—TP53—smooth muscle tissue—colon cancer	0.0013	0.0179	CbGeAlD
Acetylsalicylic acid—NFKBIA—smooth muscle tissue—colon cancer	0.00128	0.0176	CbGeAlD
Acetylsalicylic acid—HSPA5—smooth muscle tissue—colon cancer	0.00125	0.0173	CbGeAlD
Acetylsalicylic acid—TP53—renal system—colon cancer	0.00125	0.0173	CbGeAlD
Acetylsalicylic acid—NFKBIA—renal system—colon cancer	0.00123	0.017	CbGeAlD
Acetylsalicylic acid—HSPA5—renal system—colon cancer	0.00121	0.0166	CbGeAlD
Acetylsalicylic acid—TP53—lymphoid tissue—colon cancer	0.00104	0.0143	CbGeAlD
Acetylsalicylic acid—RPS6KA3—renal system—colon cancer	0.00103	0.0142	CbGeAlD
Acetylsalicylic acid—TP53—digestive system—colon cancer	0.00103	0.0142	CbGeAlD
Acetylsalicylic acid—NFKBIA—lymphoid tissue—colon cancer	0.00102	0.0141	CbGeAlD
Acetylsalicylic acid—NFKBIA—digestive system—colon cancer	0.00101	0.0139	CbGeAlD
Acetylsalicylic acid—IKBKB—embryo—colon cancer	0.001	0.0138	CbGeAlD
Acetylsalicylic acid—HSPA5—lymphoid tissue—colon cancer	0.001	0.0138	CbGeAlD
Acetylsalicylic acid—HSPA5—digestive system—colon cancer	0.00099	0.0136	CbGeAlD
Acetylsalicylic acid—TP53—bone marrow—colon cancer	0.000948	0.013	CbGeAlD
Acetylsalicylic acid—NFKBIA—bone marrow—colon cancer	0.000932	0.0128	CbGeAlD
Acetylsalicylic acid—ALB—gall bladder—colon cancer	0.000924	0.0127	CbGeAlD
Acetylsalicylic acid—HSPA5—bone marrow—colon cancer	0.000913	0.0126	CbGeAlD
Acetylsalicylic acid—TP53—vagina—colon cancer	0.000908	0.0125	CbGeAlD
Acetylsalicylic acid—NFKBIA—vagina—colon cancer	0.000893	0.0123	CbGeAlD
Acetylsalicylic acid—HSPA5—vagina—colon cancer	0.000875	0.012	CbGeAlD
Acetylsalicylic acid—RPS6KA3—lymphoid tissue—colon cancer	0.000854	0.0118	CbGeAlD
Acetylsalicylic acid—IKBKB—smooth muscle tissue—colon cancer	0.000789	0.0109	CbGeAlD
Acetylsalicylic acid—RPS6KA3—bone marrow—colon cancer	0.000778	0.0107	CbGeAlD
Acetylsalicylic acid—TP53—liver—colon cancer	0.000766	0.0105	CbGeAlD
Acetylsalicylic acid—Diabetic—Methotrexate—colon cancer	0.000757	0.0236	CcSEcCtD
Acetylsalicylic acid—NFKBIA—liver—colon cancer	0.000753	0.0104	CbGeAlD
Acetylsalicylic acid—RPS6KA3—vagina—colon cancer	0.000745	0.0103	CbGeAlD
Acetylsalicylic acid—HSPA5—liver—colon cancer	0.000738	0.0102	CbGeAlD
Acetylsalicylic acid—SLC22A7—renal system—colon cancer	0.000736	0.0101	CbGeAlD
Acetylsalicylic acid—Heartburn—Fluorouracil—colon cancer	0.000706	0.022	CcSEcCtD
Acetylsalicylic acid—Salicylate-sodium—PTGS2—colon cancer	0.000688	0.306	CrCbGaD
Acetylsalicylic acid—IKBKB—lymphoid tissue—colon cancer	0.00063	0.00868	CbGeAlD
Acetylsalicylic acid—RPS6KA3—liver—colon cancer	0.000628	0.00866	CbGeAlD
Acetylsalicylic acid—IKBKB—digestive system—colon cancer	0.000623	0.00858	CbGeAlD
Acetylsalicylic acid—PTGS1—endothelium—colon cancer	0.000607	0.00835	CbGeAlD
Acetylsalicylic acid—EDNRA—vagina—colon cancer	0.000606	0.00834	CbGeAlD
Acetylsalicylic acid—SLC22A7—digestive system—colon cancer	0.000604	0.00832	CbGeAlD
Acetylsalicylic acid—TP53—lymph node—colon cancer	0.000587	0.00809	CbGeAlD
Acetylsalicylic acid—PTGS2—endothelium—colon cancer	0.00058	0.00799	CbGeAlD
Acetylsalicylic acid—NFKBIA—lymph node—colon cancer	0.000578	0.00796	CbGeAlD
Acetylsalicylic acid—HSPA5—lymph node—colon cancer	0.000566	0.00779	CbGeAlD
Acetylsalicylic acid—PTGS1—blood vessel—colon cancer	0.000559	0.0077	CbGeAlD
Acetylsalicylic acid—IKBKB—vagina—colon cancer	0.00055	0.00757	CbGeAlD
Acetylsalicylic acid—Ulcer—Irinotecan—colon cancer	0.000536	0.0167	CcSEcCtD
Acetylsalicylic acid—PTGS2—blood vessel—colon cancer	0.000535	0.00736	CbGeAlD
Acetylsalicylic acid—Respiratory failure—Vincristine—colon cancer	0.000531	0.0165	CcSEcCtD
Acetylsalicylic acid—Ulcer—Fluorouracil—colon cancer	0.000514	0.016	CcSEcCtD
Acetylsalicylic acid—PTGS2—gall bladder—colon cancer	0.000503	0.00693	CbGeAlD
Acetylsalicylic acid—Haematemesis—Capecitabine—colon cancer	0.000489	0.0152	CcSEcCtD
Acetylsalicylic acid—RPS6KA3—lymph node—colon cancer	0.000482	0.00664	CbGeAlD
Acetylsalicylic acid—Coma—Vincristine—colon cancer	0.000476	0.0148	CcSEcCtD
Acetylsalicylic acid—IKBKB—liver—colon cancer	0.000464	0.00639	CbGeAlD
Acetylsalicylic acid—SLC22A7—liver—colon cancer	0.00045	0.0062	CbGeAlD
Acetylsalicylic acid—Coma—Fluorouracil—colon cancer	0.000444	0.0138	CcSEcCtD
Acetylsalicylic acid—Hepatotoxicity—Capecitabine—colon cancer	0.00044	0.0137	CcSEcCtD
Acetylsalicylic acid—Coagulopathy—Capecitabine—colon cancer	0.000436	0.0136	CcSEcCtD
Acetylsalicylic acid—Polyuria—Vincristine—colon cancer	0.000431	0.0134	CcSEcCtD
Acetylsalicylic acid—Deafness—Vincristine—colon cancer	0.000423	0.0132	CcSEcCtD
Acetylsalicylic acid—Eruption—Methotrexate—colon cancer	0.000411	0.0128	CcSEcCtD
Acetylsalicylic acid—Salsalate—PTGS2—colon cancer	0.000401	0.178	CrCbGaD
Acetylsalicylic acid—Meclofenamic acid—PTGS2—colon cancer	0.000395	0.176	CrCbGaD
Acetylsalicylic acid—EDNRA—lymph node—colon cancer	0.000392	0.0054	CbGeAlD
Acetylsalicylic acid—Contusion—Capecitabine—colon cancer	0.000389	0.0121	CcSEcCtD
Acetylsalicylic acid—Renal impairment—Irinotecan—colon cancer	0.000387	0.012	CcSEcCtD
Acetylsalicylic acid—Chest discomfort—Capecitabine—colon cancer	0.000384	0.0119	CcSEcCtD
Acetylsalicylic acid—Liver disorder—Methotrexate—colon cancer	0.000371	0.0115	CcSEcCtD
Acetylsalicylic acid—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.000368	0.0115	CcSEcCtD
Acetylsalicylic acid—Haematemesis—Methotrexate—colon cancer	0.000364	0.0113	CcSEcCtD
Acetylsalicylic acid—Ulcer—Capecitabine—colon cancer	0.000359	0.0112	CcSEcCtD
Acetylsalicylic acid—Hearing impaired—Capecitabine—colon cancer	0.000357	0.0111	CcSEcCtD
Acetylsalicylic acid—IKBKB—lymph node—colon cancer	0.000356	0.0049	CbGeAlD
Acetylsalicylic acid—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.000353	0.011	CcSEcCtD
Acetylsalicylic acid—Hypokalaemia—Irinotecan—colon cancer	0.000335	0.0104	CcSEcCtD
Acetylsalicylic acid—Melaena—Capecitabine—colon cancer	0.000332	0.0103	CcSEcCtD
Acetylsalicylic acid—ABCB1—blood vessel—colon cancer	0.000331	0.00456	CbGeAlD
Acetylsalicylic acid—Hepatotoxicity—Methotrexate—colon cancer	0.000327	0.0102	CcSEcCtD
Acetylsalicylic acid—PTGS2—embryo—colon cancer	0.000319	0.00439	CbGeAlD
Acetylsalicylic acid—CYP2C8—renal system—colon cancer	0.000311	0.00429	CbGeAlD
Acetylsalicylic acid—Mefenamic acid—PTGS2—colon cancer	0.000307	0.137	CrCbGaD
Acetylsalicylic acid—CYP2C19—digestive system—colon cancer	0.000293	0.00403	CbGeAlD
Acetylsalicylic acid—Diabetes mellitus—Capecitabine—colon cancer	0.000283	0.00882	CcSEcCtD
Acetylsalicylic acid—Polyuria—Capecitabine—colon cancer	0.000281	0.00874	CcSEcCtD
Acetylsalicylic acid—Sweating—Vincristine—colon cancer	0.000279	0.00869	CcSEcCtD
Acetylsalicylic acid—Deafness—Capecitabine—colon cancer	0.000276	0.00857	CcSEcCtD
Acetylsalicylic acid—Vascular purpura—Capecitabine—colon cancer	0.000276	0.00857	CcSEcCtD
Acetylsalicylic acid—PTGS1—epithelium—colon cancer	0.000272	0.00375	CbGeAlD
Acetylsalicylic acid—Sweating—Irinotecan—colon cancer	0.000272	0.00847	CcSEcCtD
Acetylsalicylic acid—ALB—liver—colon cancer	0.000271	0.00373	CbGeAlD
Acetylsalicylic acid—Ulcer—Methotrexate—colon cancer	0.000267	0.00832	CcSEcCtD
Acetylsalicylic acid—PTGS1—smooth muscle tissue—colon cancer	0.000262	0.00361	CbGeAlD
Acetylsalicylic acid—PTGS2—epithelium—colon cancer	0.00026	0.00358	CbGeAlD
Acetylsalicylic acid—Renal impairment—Capecitabine—colon cancer	0.000259	0.00806	CcSEcCtD
Acetylsalicylic acid—Thirst—Capecitabine—colon cancer	0.000259	0.00806	CcSEcCtD
Acetylsalicylic acid—CYP2C19—vagina—colon cancer	0.000258	0.00356	CbGeAlD
Acetylsalicylic acid—Respiratory failure—Methotrexate—colon cancer	0.000257	0.00801	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Irinotecan—colon cancer	0.000256	0.00797	CcSEcCtD
Acetylsalicylic acid—Purpura—Capecitabine—colon cancer	0.000256	0.00796	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Irinotecan—colon cancer	0.000255	0.00793	CcSEcCtD
Acetylsalicylic acid—PTGS1—renal system—colon cancer	0.000253	0.00348	CbGeAlD
Acetylsalicylic acid—PTGS2—smooth muscle tissue—colon cancer	0.000251	0.00345	CbGeAlD
Acetylsalicylic acid—Melaena—Methotrexate—colon cancer	0.000247	0.00768	CcSEcCtD
Acetylsalicylic acid—Salicylic acid—PTGS2—colon cancer	0.000247	0.11	CrCbGaD
Acetylsalicylic acid—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.000247	0.00767	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Fluorouracil—colon cancer	0.000245	0.00763	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Fluorouracil—colon cancer	0.000244	0.00759	CcSEcCtD
Acetylsalicylic acid—PTGS2—renal system—colon cancer	0.000241	0.00333	CbGeAlD
Acetylsalicylic acid—Flushing—Irinotecan—colon cancer	0.000236	0.00736	CcSEcCtD
Acetylsalicylic acid—Coma—Methotrexate—colon cancer	0.000231	0.00719	CcSEcCtD
Acetylsalicylic acid—CYP2C9—digestive system—colon cancer	0.000227	0.00313	CbGeAlD
Acetylsalicylic acid—CYP2C8—vagina—colon cancer	0.000226	0.00311	CbGeAlD
Acetylsalicylic acid—Hypokalaemia—Capecitabine—colon cancer	0.000224	0.00698	CcSEcCtD
Acetylsalicylic acid—CYP2C19—liver—colon cancer	0.000218	0.003	CbGeAlD
Acetylsalicylic acid—Influenza—Capecitabine—colon cancer	0.000213	0.00663	CcSEcCtD
Acetylsalicylic acid—Asthma—Capecitabine—colon cancer	0.000213	0.00663	CcSEcCtD
Acetylsalicylic acid—Diabetes mellitus—Methotrexate—colon cancer	0.000211	0.00656	CcSEcCtD
Acetylsalicylic acid—Anaemia—Vincristine—colon cancer	0.000211	0.00655	CcSEcCtD
Acetylsalicylic acid—Salicylic acid—ABCB1—colon cancer	0.00021	0.0933	CrCbGaD
Acetylsalicylic acid—Agitation—Vincristine—colon cancer	0.000209	0.00651	CcSEcCtD
Acetylsalicylic acid—Polyuria—Methotrexate—colon cancer	0.000209	0.0065	CcSEcCtD
Acetylsalicylic acid—ALB—lymph node—colon cancer	0.000208	0.00286	CbGeAlD
Acetylsalicylic acid—PTGS1—digestive system—colon cancer	0.000207	0.00285	CbGeAlD
Acetylsalicylic acid—Anaemia—Irinotecan—colon cancer	0.000205	0.00638	CcSEcCtD
Acetylsalicylic acid—Vertigo—Vincristine—colon cancer	0.000205	0.00637	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Vincristine—colon cancer	0.000204	0.00634	CcSEcCtD
Acetylsalicylic acid—PTGS2—lymphoid tissue—colon cancer	0.0002	0.00276	CbGeAlD
Acetylsalicylic acid—Vertigo—Irinotecan—colon cancer	0.000199	0.0062	CcSEcCtD
Acetylsalicylic acid—Syncope—Irinotecan—colon cancer	0.000199	0.00619	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Irinotecan—colon cancer	0.000199	0.00618	CcSEcCtD
Acetylsalicylic acid—PTGS2—digestive system—colon cancer	0.000198	0.00273	CbGeAlD
Acetylsalicylic acid—Convulsion—Vincristine—colon cancer	0.000197	0.00614	CcSEcCtD
Acetylsalicylic acid—ABCB1—embryo—colon cancer	0.000197	0.00272	CbGeAlD
Acetylsalicylic acid—Hypertension—Vincristine—colon cancer	0.000197	0.00612	CcSEcCtD
Acetylsalicylic acid—Anaemia—Fluorouracil—colon cancer	0.000196	0.00611	CcSEcCtD
Acetylsalicylic acid—Loss of consciousness—Irinotecan—colon cancer	0.000195	0.00607	CcSEcCtD
Acetylsalicylic acid—Hypertension—Irinotecan—colon cancer	0.000192	0.00596	CcSEcCtD
Acetylsalicylic acid—CYP2C8—liver—colon cancer	0.00019	0.00262	CbGeAlD
Acetylsalicylic acid—Leukopenia—Fluorouracil—colon cancer	0.00019	0.00592	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Vincristine—colon cancer	0.000186	0.00578	CcSEcCtD
Acetylsalicylic acid—Convulsion—Fluorouracil—colon cancer	0.000184	0.00573	CcSEcCtD
Acetylsalicylic acid—PTGS1—vagina—colon cancer	0.000183	0.00252	CbGeAlD
Acetylsalicylic acid—PTGS2—bone marrow—colon cancer	0.000183	0.00251	CbGeAlD
Acetylsalicylic acid—Confusional state—Irinotecan—colon cancer	0.000183	0.00568	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Vincristine—colon cancer	0.000182	0.00566	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Irinotecan—colon cancer	0.000181	0.00563	CcSEcCtD
Acetylsalicylic acid—Chest pain—Fluorouracil—colon cancer	0.000181	0.00563	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Vincristine—colon cancer	0.00018	0.00559	CcSEcCtD
Acetylsalicylic acid—Shock—Irinotecan—colon cancer	0.000178	0.00554	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Irinotecan—colon cancer	0.000177	0.00552	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Irinotecan—colon cancer	0.000175	0.00545	CcSEcCtD
Acetylsalicylic acid—PTGS2—vagina—colon cancer	0.000175	0.00241	CbGeAlD
Acetylsalicylic acid—Confusional state—Fluorouracil—colon cancer	0.000175	0.00544	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Fluorouracil—colon cancer	0.000173	0.00539	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Capecitabine—colon cancer	0.000171	0.00533	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Capecitabine—colon cancer	0.000171	0.00531	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Fluorouracil—colon cancer	0.00017	0.00528	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Fluorouracil—colon cancer	0.000169	0.00527	CcSEcCtD
Acetylsalicylic acid—CYP2C9—liver—colon cancer	0.000169	0.00233	CbGeAlD
Acetylsalicylic acid—Dyspnoea—Irinotecan—colon cancer	0.000161	0.00502	CcSEcCtD
Acetylsalicylic acid—ABCB1—epithelium—colon cancer	0.000161	0.00222	CbGeAlD
Acetylsalicylic acid—Somnolence—Irinotecan—colon cancer	0.000161	0.00501	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Irinotecan—colon cancer	0.000159	0.00496	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Capecitabine—colon cancer	0.000159	0.00495	CcSEcCtD
Acetylsalicylic acid—Asthma—Methotrexate—colon cancer	0.000159	0.00494	CcSEcCtD
Acetylsalicylic acid—Flushing—Capecitabine—colon cancer	0.000158	0.00492	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Fluorouracil—colon cancer	0.000155	0.00481	CcSEcCtD
Acetylsalicylic acid—Somnolence—Fluorouracil—colon cancer	0.000154	0.0048	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Fluorouracil—colon cancer	0.000153	0.00475	CcSEcCtD
Acetylsalicylic acid—ABCB1—renal system—colon cancer	0.000149	0.00206	CbGeAlD
Acetylsalicylic acid—Feeling abnormal—Irinotecan—colon cancer	0.000149	0.00464	CcSEcCtD
Acetylsalicylic acid—PTGS2—liver—colon cancer	0.000148	0.00203	CbGeAlD
Acetylsalicylic acid—Feeling abnormal—Fluorouracil—colon cancer	0.000143	0.00445	CcSEcCtD
Acetylsalicylic acid—Drowsiness—Methotrexate—colon cancer	0.000141	0.0044	CcSEcCtD
Acetylsalicylic acid—Urticaria—Fluorouracil—colon cancer	0.000138	0.00429	CcSEcCtD
Acetylsalicylic acid—Anaemia—Capecitabine—colon cancer	0.000137	0.00427	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Vincristine—colon cancer	0.000137	0.00426	CcSEcCtD
Acetylsalicylic acid—Sweating—Methotrexate—colon cancer	0.000136	0.00422	CcSEcCtD
Acetylsalicylic acid—Vertigo—Capecitabine—colon cancer	0.000133	0.00415	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Irinotecan—colon cancer	0.000133	0.00415	CcSEcCtD
Acetylsalicylic acid—Syncope—Capecitabine—colon cancer	0.000133	0.00414	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Capecitabine—colon cancer	0.000133	0.00413	CcSEcCtD
Acetylsalicylic acid—Loss of consciousness—Capecitabine—colon cancer	0.00013	0.00406	CcSEcCtD
Acetylsalicylic acid—Hypertension—Capecitabine—colon cancer	0.000128	0.00399	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Fluorouracil—colon cancer	0.000128	0.00397	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Methotrexate—colon cancer	0.000128	0.00397	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Vincristine—colon cancer	0.000127	0.00396	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Methotrexate—colon cancer	0.000127	0.00395	CcSEcCtD
Acetylsalicylic acid—Chest pain—Capecitabine—colon cancer	0.000126	0.00393	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Capecitabine—colon cancer	0.000126	0.00393	CcSEcCtD
Acetylsalicylic acid—ABCB1—lymphoid tissue—colon cancer	0.000124	0.00171	CbGeAlD
Acetylsalicylic acid—Diarrhoea—Irinotecan—colon cancer	0.000124	0.00385	CcSEcCtD
Acetylsalicylic acid—Dizziness—Vincristine—colon cancer	0.000123	0.00382	CcSEcCtD
Acetylsalicylic acid—Pruritus—Fluorouracil—colon cancer	0.000123	0.00382	CcSEcCtD
Acetylsalicylic acid—ABCB1—digestive system—colon cancer	0.000122	0.00169	CbGeAlD
Acetylsalicylic acid—Confusional state—Capecitabine—colon cancer	0.000122	0.0038	CcSEcCtD
Acetylsalicylic acid—Dizziness—Irinotecan—colon cancer	0.00012	0.00372	CcSEcCtD
Acetylsalicylic acid—Shock—Capecitabine—colon cancer	0.000119	0.00371	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Fluorouracil—colon cancer	0.000119	0.00369	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Capecitabine—colon cancer	0.000119	0.00369	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Methotrexate—colon cancer	0.000118	0.00368	CcSEcCtD
Acetylsalicylic acid—PTGS1—lymph node—colon cancer	0.000118	0.00163	CbGeAlD
Acetylsalicylic acid—Tachycardia—Capecitabine—colon cancer	0.000118	0.00368	CcSEcCtD
Acetylsalicylic acid—Vomiting—Vincristine—colon cancer	0.000118	0.00368	CcSEcCtD
Acetylsalicylic acid—Rash—Vincristine—colon cancer	0.000117	0.00365	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Capecitabine—colon cancer	0.000117	0.00364	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Vincristine—colon cancer	0.000117	0.00364	CcSEcCtD
Acetylsalicylic acid—Vomiting—Irinotecan—colon cancer	0.000115	0.00358	CcSEcCtD
Acetylsalicylic acid—Dizziness—Fluorouracil—colon cancer	0.000115	0.00357	CcSEcCtD
Acetylsalicylic acid—Rash—Irinotecan—colon cancer	0.000114	0.00355	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Irinotecan—colon cancer	0.000114	0.00355	CcSEcCtD
Acetylsalicylic acid—PTGS2—lymph node—colon cancer	0.000113	0.00156	CbGeAlD
Acetylsalicylic acid—ABCB1—bone marrow—colon cancer	0.000113	0.00156	CbGeAlD
Acetylsalicylic acid—Nausea—Vincristine—colon cancer	0.00011	0.00344	CcSEcCtD
Acetylsalicylic acid—Vomiting—Fluorouracil—colon cancer	0.00011	0.00343	CcSEcCtD
Acetylsalicylic acid—Rash—Fluorouracil—colon cancer	0.000109	0.0034	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Fluorouracil—colon cancer	0.000109	0.0034	CcSEcCtD
Acetylsalicylic acid—ABCB1—vagina—colon cancer	0.000108	0.00149	CbGeAlD
Acetylsalicylic acid—Dyspnoea—Capecitabine—colon cancer	0.000108	0.00336	CcSEcCtD
Acetylsalicylic acid—Nausea—Irinotecan—colon cancer	0.000108	0.00335	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Capecitabine—colon cancer	0.000107	0.00332	CcSEcCtD
Acetylsalicylic acid—Nausea—Fluorouracil—colon cancer	0.000103	0.0032	CcSEcCtD
Acetylsalicylic acid—Anaemia—Methotrexate—colon cancer	0.000102	0.00318	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Capecitabine—colon cancer	9.98e-05	0.00311	CcSEcCtD
Acetylsalicylic acid—Vertigo—Methotrexate—colon cancer	9.93e-05	0.00309	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Methotrexate—colon cancer	9.89e-05	0.00308	CcSEcCtD
Acetylsalicylic acid—Urticaria—Capecitabine—colon cancer	9.63e-05	0.00299	CcSEcCtD
Acetylsalicylic acid—Convulsion—Methotrexate—colon cancer	9.58e-05	0.00298	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Methotrexate—colon cancer	9.41e-05	0.00293	CcSEcCtD
Acetylsalicylic acid—Chest pain—Methotrexate—colon cancer	9.41e-05	0.00293	CcSEcCtD
Acetylsalicylic acid—ABCB1—liver—colon cancer	9.13e-05	0.00126	CbGeAlD
Acetylsalicylic acid—Confusional state—Methotrexate—colon cancer	9.09e-05	0.00283	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Methotrexate—colon cancer	9.02e-05	0.00281	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Capecitabine—colon cancer	8.93e-05	0.00278	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Methotrexate—colon cancer	8.83e-05	0.00275	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Methotrexate—colon cancer	8.72e-05	0.00271	CcSEcCtD
Acetylsalicylic acid—Pruritus—Capecitabine—colon cancer	8.57e-05	0.00267	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Capecitabine—colon cancer	8.29e-05	0.00258	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Methotrexate—colon cancer	8.04e-05	0.0025	CcSEcCtD
Acetylsalicylic acid—Somnolence—Methotrexate—colon cancer	8.02e-05	0.00249	CcSEcCtD
Acetylsalicylic acid—Dizziness—Capecitabine—colon cancer	8.01e-05	0.00249	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Methotrexate—colon cancer	7.94e-05	0.00247	CcSEcCtD
Acetylsalicylic acid—Vomiting—Capecitabine—colon cancer	7.7e-05	0.0024	CcSEcCtD
Acetylsalicylic acid—Rash—Capecitabine—colon cancer	7.64e-05	0.00238	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Capecitabine—colon cancer	7.63e-05	0.00237	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Methotrexate—colon cancer	7.43e-05	0.00231	CcSEcCtD
Acetylsalicylic acid—Nausea—Capecitabine—colon cancer	7.2e-05	0.00224	CcSEcCtD
Acetylsalicylic acid—Urticaria—Methotrexate—colon cancer	7.17e-05	0.00223	CcSEcCtD
Acetylsalicylic acid—ABCB1—lymph node—colon cancer	7e-05	0.000964	CbGeAlD
Acetylsalicylic acid—Hypersensitivity—Methotrexate—colon cancer	6.65e-05	0.00207	CcSEcCtD
Acetylsalicylic acid—Pruritus—Methotrexate—colon cancer	6.38e-05	0.00199	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Methotrexate—colon cancer	6.17e-05	0.00192	CcSEcCtD
Acetylsalicylic acid—Dizziness—Methotrexate—colon cancer	5.96e-05	0.00186	CcSEcCtD
Acetylsalicylic acid—Vomiting—Methotrexate—colon cancer	5.73e-05	0.00178	CcSEcCtD
Acetylsalicylic acid—Rash—Methotrexate—colon cancer	5.69e-05	0.00177	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Methotrexate—colon cancer	5.68e-05	0.00177	CcSEcCtD
Acetylsalicylic acid—Nausea—Methotrexate—colon cancer	5.36e-05	0.00167	CcSEcCtD
Acetylsalicylic acid—IKBKB—Innate Immune System—CDKN1A—colon cancer	1.03e-05	9.52e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—BCL2L1—colon cancer	1.03e-05	9.52e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—GPCR downstream signaling—PIK3CA—colon cancer	1.03e-05	9.46e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Disease—HRAS—colon cancer	1.02e-05	9.37e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling by GPCR—KRAS—colon cancer	1.02e-05	9.35e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling by GPCR—KRAS—colon cancer	1.02e-05	9.35e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—SRC—colon cancer	1.01e-05	9.32e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	9.94e-06	9.15e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—CDKN1A—colon cancer	9.93e-06	9.14e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—FGFR3—colon cancer	9.89e-06	9.1e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—VEGFA—colon cancer	9.86e-06	9.08e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	9.85e-06	9.07e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—EP300—colon cancer	9.84e-06	9.06e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Immune System—EGFR—colon cancer	9.82e-06	9.05e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	9.74e-06	8.97e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—NRAS—colon cancer	9.74e-06	8.97e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	9.62e-06	8.85e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	9.59e-06	8.83e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—SRC—colon cancer	9.57e-06	8.81e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Immune System—PIK3CA—colon cancer	9.54e-06	8.78e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	9.41e-06	8.66e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	9.41e-06	8.66e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling by GPCR—PIK3CA—colon cancer	9.33e-06	8.59e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling by GPCR—PIK3CA—colon cancer	9.33e-06	8.59e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—CASP3—colon cancer	9.3e-06	8.57e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Immune System—KRAS—colon cancer	9.28e-06	8.54e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Metabolism—PIK3CA—colon cancer	9.21e-06	8.48e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—NRAS—colon cancer	9.21e-06	8.48e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—CASP3—colon cancer	9.2e-06	8.47e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—SRC—colon cancer	9.19e-06	8.46e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—MYC—colon cancer	9.07e-06	8.35e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—CCND1—colon cancer	9.06e-06	8.34e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—TGFB1—colon cancer	9.05e-06	8.33e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Disease—AKT1—colon cancer	8.99e-06	8.27e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—CTNNB1—colon cancer	8.97e-06	8.26e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—CCND1—colon cancer	8.95e-06	8.24e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	8.89e-06	8.18e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—EGFR—colon cancer	8.88e-06	8.17e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—CTNNB1—colon cancer	8.87e-06	8.16e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—NRAS—colon cancer	8.84e-06	8.14e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Immune System—HRAS—colon cancer	8.82e-06	8.12e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—CDKN1A—colon cancer	8.76e-06	8.07e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—CDKN1A—colon cancer	8.66e-06	7.97e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling by GPCR—HRAS—colon cancer	8.63e-06	7.95e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling by GPCR—HRAS—colon cancer	8.63e-06	7.95e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Immune System—PIK3CA—colon cancer	8.53e-06	7.85e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—GPCR downstream signaling—AKT1—colon cancer	8.4e-06	7.73e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—EGFR—colon cancer	8.39e-06	7.72e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—KRAS—colon cancer	8.38e-06	7.72e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CDH1—colon cancer	8.35e-06	7.69e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—EP300—colon cancer	8.34e-06	7.68e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—CASP3—colon cancer	8.32e-06	7.66e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—CASP3—colon cancer	8.32e-06	7.66e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	8.29e-06	7.63e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—EP300—colon cancer	8.24e-06	7.59e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	8.19e-06	7.54e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	8.16e-06	7.52e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—SRC—colon cancer	8.11e-06	7.46e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—CCND1—colon cancer	8.1e-06	7.45e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—CCND1—colon cancer	8.1e-06	7.45e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.09e-06	7.44e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—EGFR—colon cancer	8.06e-06	7.42e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.04e-06	7.4e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—CTNNB1—colon cancer	8.02e-06	7.38e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—CTNNB1—colon cancer	8.02e-06	7.38e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—SRC—colon cancer	8.01e-06	7.38e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—ABCB1—colon cancer	8.01e-06	7.38e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—KRAS—colon cancer	7.92e-06	7.3e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	7.9e-06	7.27e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—VEGFA—colon cancer	7.9e-06	7.27e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Immune System—HRAS—colon cancer	7.89e-06	7.26e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—TYMS—colon cancer	7.87e-06	7.25e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—CDKN1A—colon cancer	7.83e-06	7.21e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—CDKN1A—colon cancer	7.83e-06	7.21e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—VEGFA—colon cancer	7.8e-06	7.19e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—NRAS—colon cancer	7.8e-06	7.18e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Immune System—AKT1—colon cancer	7.79e-06	7.17e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—NRAS—colon cancer	7.71e-06	7.1e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—PIK3CA—colon cancer	7.7e-06	7.09e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling by GPCR—AKT1—colon cancer	7.62e-06	7.02e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling by GPCR—AKT1—colon cancer	7.62e-06	7.02e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—KRAS—colon cancer	7.61e-06	7.01e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Metabolism—AKT1—colon cancer	7.53e-06	6.93e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—EP300—colon cancer	7.45e-06	6.86e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—EP300—colon cancer	7.45e-06	6.86e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—TP53—colon cancer	7.45e-06	6.86e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—PIK3CA—colon cancer	7.28e-06	6.7e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—MYC—colon cancer	7.26e-06	6.69e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—TGFB1—colon cancer	7.25e-06	6.67e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—SRC—colon cancer	7.25e-06	6.67e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—SRC—colon cancer	7.25e-06	6.67e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.22e-06	6.64e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—MYC—colon cancer	7.18e-06	6.61e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—TGFB1—colon cancer	7.16e-06	6.6e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—HRAS—colon cancer	7.13e-06	6.56e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—EGFR—colon cancer	7.11e-06	6.54e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—VEGFA—colon cancer	7.06e-06	6.5e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—VEGFA—colon cancer	7.06e-06	6.5e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—EGFR—colon cancer	7.02e-06	6.47e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—PIK3CA—colon cancer	6.99e-06	6.44e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—NRAS—colon cancer	6.97e-06	6.42e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—NRAS—colon cancer	6.97e-06	6.42e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Immune System—AKT1—colon cancer	6.97e-06	6.41e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	6.77e-06	6.24e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—HRAS—colon cancer	6.74e-06	6.2e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—KRAS—colon cancer	6.71e-06	6.18e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	6.67e-06	6.14e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—KRAS—colon cancer	6.64e-06	6.11e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	6.58e-06	6.06e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.5e-06	5.99e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—MYC—colon cancer	6.49e-06	5.98e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—MYC—colon cancer	6.49e-06	5.98e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—TGFB1—colon cancer	6.48e-06	5.96e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—TGFB1—colon cancer	6.48e-06	5.96e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—HRAS—colon cancer	6.47e-06	5.96e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—FGFR3—colon cancer	6.39e-06	5.89e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—ABCB1—colon cancer	6.36e-06	5.86e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.36e-06	5.86e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—EGFR—colon cancer	6.35e-06	5.85e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—EGFR—colon cancer	6.35e-06	5.85e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.32e-06	5.82e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—AKT1—colon cancer	6.29e-06	5.79e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—TYMS—colon cancer	6.25e-06	5.75e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CTNNB1—colon cancer	6.17e-06	5.68e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—PIK3CA—colon cancer	6.17e-06	5.68e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—PIK3CA—colon cancer	6.1e-06	5.61e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.06e-06	5.58e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CDKN1A—colon cancer	6.02e-06	5.55e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—KRAS—colon cancer	6e-06	5.52e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—KRAS—colon cancer	6e-06	5.52e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—TP53—colon cancer	5.97e-06	5.49e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—FGFR3—colon cancer	5.96e-06	5.49e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—AKT1—colon cancer	5.95e-06	5.48e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—APC—colon cancer	5.87e-06	5.4e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—EP300—colon cancer	5.78e-06	5.32e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—EP300—colon cancer	5.73e-06	5.28e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—AKT1—colon cancer	5.71e-06	5.26e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—HRAS—colon cancer	5.71e-06	5.25e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.68e-06	5.23e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—HRAS—colon cancer	5.64e-06	5.19e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—SRC—colon cancer	5.62e-06	5.17e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PPARG—colon cancer	5.57e-06	5.13e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—SRC—colon cancer	5.57e-06	5.13e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—BRAF—colon cancer	5.52e-06	5.08e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—PIK3CA—colon cancer	5.51e-06	5.08e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—PIK3CA—colon cancer	5.51e-06	5.08e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—APC—colon cancer	5.48e-06	5.04e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—VEGFA—colon cancer	5.47e-06	5.04e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—NRAS—colon cancer	5.41e-06	4.98e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—NRAS—colon cancer	5.36e-06	4.94e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—TP53—colon cancer	5.33e-06	4.91e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—TP53—colon cancer	5.33e-06	4.91e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.29e-06	4.87e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.26e-06	4.84e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.18e-06	4.77e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—ABCB1—colon cancer	5.18e-06	4.77e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—BRAF—colon cancer	5.15e-06	4.74e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—ABCB1—colon cancer	5.15e-06	4.74e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—HRAS—colon cancer	5.1e-06	4.7e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—HRAS—colon cancer	5.1e-06	4.7e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—TYMS—colon cancer	5.08e-06	4.68e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—TYMS—colon cancer	5.05e-06	4.65e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—AKT1—colon cancer	5.04e-06	4.64e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—TGFB1—colon cancer	5.02e-06	4.62e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—AKT1—colon cancer	4.98e-06	4.58e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—EGFR—colon cancer	4.89e-06	4.5e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.81e-06	4.43e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.72e-06	4.35e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—KRAS—colon cancer	4.65e-06	4.28e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—ABCB1—colon cancer	4.62e-06	4.25e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—KRAS—colon cancer	4.62e-06	4.25e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—TYMS—colon cancer	4.54e-06	4.18e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—AKT1—colon cancer	4.5e-06	4.15e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—AKT1—colon cancer	4.5e-06	4.15e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—TYMS—colon cancer	4.43e-06	4.08e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PPARG—colon cancer	4.43e-06	4.07e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PTGS2—colon cancer	4.39e-06	4.04e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.31e-06	3.96e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—PIK3CA—colon cancer	4.27e-06	3.94e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—PIK3CA—colon cancer	4.24e-06	3.9e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—ABCB1—colon cancer	4.21e-06	3.88e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—TYMS—colon cancer	4.14e-06	3.81e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CASP3—colon cancer	4.14e-06	3.81e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—TP53—colon cancer	4.13e-06	3.81e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CCND1—colon cancer	4.03e-06	3.71e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CTNNB1—colon cancer	3.99e-06	3.67e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—HRAS—colon cancer	3.95e-06	3.64e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—HRAS—colon cancer	3.92e-06	3.61e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.91e-06	3.6e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CDKN1A—colon cancer	3.9e-06	3.59e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.89e-06	3.58e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—CTNNB1—colon cancer	3.72e-06	3.42e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—EP300—colon cancer	3.71e-06	3.41e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—EP300—colon cancer	3.65e-06	3.36e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—CDKN1A—colon cancer	3.63e-06	3.35e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—SRC—colon cancer	3.6e-06	3.32e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PPARG—colon cancer	3.6e-06	3.32e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PPARG—colon cancer	3.58e-06	3.3e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—VEGFA—colon cancer	3.51e-06	3.23e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.49e-06	3.22e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—AKT1—colon cancer	3.49e-06	3.21e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—NRAS—colon cancer	3.47e-06	3.19e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—AKT1—colon cancer	3.46e-06	3.19e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—EP300—colon cancer	3.46e-06	3.18e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—SRC—colon cancer	3.36e-06	3.1e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—NRAS—colon cancer	3.23e-06	2.98e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MYC—colon cancer	3.23e-06	2.97e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—TGFB1—colon cancer	3.22e-06	2.97e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PPARG—colon cancer	3.21e-06	2.96e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.19e-06	2.93e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—EGFR—colon cancer	3.16e-06	2.91e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PPARG—colon cancer	3.14e-06	2.89e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—MYC—colon cancer	3.01e-06	2.77e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—TGFB1—colon cancer	3.01e-06	2.77e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—KRAS—colon cancer	2.98e-06	2.75e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—EGFR—colon cancer	2.95e-06	2.71e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PPARG—colon cancer	2.93e-06	2.7e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—EP300—colon cancer	2.9e-06	2.67e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PTGS2—colon cancer	2.83e-06	2.61e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PTGS2—colon cancer	2.82e-06	2.59e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—KRAS—colon cancer	2.78e-06	2.56e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—PIK3CA—colon cancer	2.74e-06	2.52e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PIK3CA—colon cancer	2.7e-06	2.48e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—TP53—colon cancer	2.65e-06	2.44e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—PIK3CA—colon cancer	2.56e-06	2.35e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—HRAS—colon cancer	2.54e-06	2.34e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PTGS2—colon cancer	2.53e-06	2.33e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PTGS2—colon cancer	2.47e-06	2.27e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—HRAS—colon cancer	2.37e-06	2.18e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—EP300—colon cancer	2.36e-06	2.17e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—EP300—colon cancer	2.34e-06	2.16e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PTGS2—colon cancer	2.31e-06	2.12e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—AKT1—colon cancer	2.24e-06	2.06e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—AKT1—colon cancer	2.2e-06	2.03e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PIK3CA—colon cancer	2.14e-06	1.97e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—EP300—colon cancer	2.1e-06	1.94e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—AKT1—colon cancer	2.09e-06	1.92e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—EP300—colon cancer	2.05e-06	1.89e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—EP300—colon cancer	1.92e-06	1.77e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—AKT1—colon cancer	1.75e-06	1.61e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PIK3CA—colon cancer	1.74e-06	1.6e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PIK3CA—colon cancer	1.73e-06	1.6e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PIK3CA—colon cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PIK3CA—colon cancer	1.52e-06	1.4e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—AKT1—colon cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PIK3CA—colon cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—AKT1—colon cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—AKT1—colon cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—AKT1—colon cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—AKT1—colon cancer	1.16e-06	1.07e-05	CbGpPWpGaD
